NUPLAZID net product sales guidance is narrowed to the high end of the prior range and is now expected to be $600 to $610 million. DAYBUE net product sales guidance is narrowed to the low end of the prior range and is now expected to be $340 to $350 million.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M
- ACAD Upcoming Earnings Report: What to Expect?
- Health Canada grants approval of Acadia’s Rett syndrome treatment
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Acadia Pharmaceuticals reinstated with a Market Perform at Raymond James